Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486869 · ClinicalTrials.gov registry record · Phase 2
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
A Phase 2 study, sponsored by University of Miami.
- Not yet
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT07486869 is a Phase 2 study that has not yet begun recruiting, run by University of Miami. The registered enrollment target is 5 participants.
The verdict
NCT07486869, a Phase 2 study, has not yet begun recruiting, sponsored by University of Miami.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.
Interventions
- DRUG Emapalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07486869
The ClinicalTrials.gov registry entry for NCT07486869 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emapalumab is the first listed.
NCT07486869 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07486869 about?
NCT07486869 is a clinical study titled "Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study". This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage...
What is the current status of trial NCT07486869?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2026-07. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07486869?
The interventions under investigation include: Emapalumab (DRUG).
Who is sponsoring clinical trial NCT07486869?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.